Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of 17.84 billion. The enterprise value is 22.31 billion.

Market Cap	17.84B
Enterprise Value	22.31B

Important Dates

The last earnings date was Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.14%
Shares Change (QoQ)	+1.59%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.79B

Valuation Ratios

The trailing PE ratio is 52.65.

PE Ratio	52.65
Forward PE	n/a
PS Ratio	1.40
PB Ratio	1.77
P/TBV Ratio	n/a
P/FCF Ratio	16.96
P/OCF Ratio	13.74
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.44, with an EV/FCF ratio of 21.21.

EV / Earnings	65.84
EV / Sales	1.68
EV / EBITDA	7.44
EV / EBIT	13.83
EV / FCF	21.21

Financial Position

The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.55.

Current Ratio	1.13
Quick Ratio	0.79
Debt / Equity	0.55
Debt / EBITDA	1.93
Debt / FCF	5.28
Interest Coverage	13.16

Financial Efficiency

Return on equity (ROE) is 3.26% and return on invested capital (ROIC) is 5.98%.

Return on Equity (ROE)	3.26%
Return on Assets (ROA)	4.21%
Return on Invested Capital (ROIC)	5.98%
Return on Capital Employed (ROCE)	10.21%
Revenue Per Employee	865,547
Profits Per Employee	22,969
Employee Count	14,754
Asset Turnover	0.55
Inventory Turnover	1.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.34% in the last 52 weeks. The beta is 0.17, so Astellas Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+6.34%
50-Day Moving Average	9.64
200-Day Moving Average	10.58
Relative Strength Index (RSI)	65.72
Average Volume (20 Days)	324,138

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of 12.77 billion and earned 338.88 million in profits. Earnings per share was 0.19.

Revenue	12.77B
Gross Profit	10.44B
Operating Income	1.55B
Pretax Income	208.60M
Net Income	338.88M
EBITDA	2.88B
EBIT	1.55B
Earnings Per Share (EPS)	0.19

Full Income Statement

Balance Sheet

The company has 1.26 billion in cash and 5.55 billion in debt, giving a net cash position of -4.29 billion.

Cash & Cash Equivalents	1.26B
Total Debt	5.55B
Net Cash	-4.29B
Net Cash Per Share	n/a
Equity (Book Value)	10.11B
Book Value Per Share	5.64
Working Capital	933.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.30 billion and capital expenditures -247.10 million, giving a free cash flow of 1.05 billion.

Operating Cash Flow	1.30B
Capital Expenditures	-247.10M
Free Cash Flow	1.05B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 81.74%, with operating and profit margins of 12.16% and 2.65%.

Gross Margin	81.74%
Operating Margin	12.16%
Pretax Margin	1.63%
Profit Margin	2.65%
EBITDA Margin	22.57%
EBIT Margin	12.16%
FCF Margin	8.24%

Dividends & Yields

This stock pays an annual dividend of 0.51, which amounts to a dividend yield of 5.02%.

Dividend Per Share	0.51
Dividend Yield	5.02%
Dividend Growth (YoY)	8.56%
Years of Dividend Growth	2
Payout Ratio	254.19%
Buyback Yield	0.14%
Shareholder Yield	5.16%
Earnings Yield	1.90%
FCF Yield	5.89%

Dividend Details

Stock Splits

The last stock split was on April 2, 2014. It was a forward split with a ratio of 1.25.

Last Split Date	Apr 2, 2014
Split Type	Forward
Split Ratio	1.25

Scores

Astellas Pharma has an Altman Z-Score of 2.1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.1
Piotroski F-Score	n/a